insights_auto
Why is TNG down 2.57%?
Dive Deeperchevron_right
TNG:EPA
Transgene SA
€0.76
arrow_downward
-2.57%(-0.020) 1D
Nov 4, 5:35:24 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TNG...
Open
€0.78
High
€0.78
Low
€0.74
Mkt. cap
196.10M
Avg. vol.
91.60K
Volume
145.29K
52-wk high
€1.50
52-wk low
€0.67
EPS
-€0.17
Shares outstanding
278.56M
No. of employees
152
Open
€0.78
High
€0.78
Low
€0.74
Mkt. cap
196.10M
Avg. vol.
91.60K
Volume
145.29K
52-wk high
€1.50
52-wk low
€0.67
EPS
-€0.17
Shares outstanding
278.56M
No. of employees
152
News stories
From web sources and news partners
FinancialContent
·
38 minutes ago
U.S. Physical Therapy (NYSE:USPH) reports strong Q3 2026
Yahoo Finance
·
50 minutes ago
Update: Dow Logs Best Day Since April 2025 Following US Midterm Elections
shattered.io
·
45 minutes ago
S&P Earnings Jump 30.2% as Big Tech Cash Flow Sinks [2026]
MarketWatch
·
1 hour ago
Big Tech is driving a historic divide in the S&P 500. Why investors need to take notice.
Profile
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
About Transgene SA